Cancer Scenario in India

Cancer is one of the leading causes of

Year Wise Total Cancer Prevalance in India

adult deaths worldwide. In India, the

Cancer estimated indirectly that about

635,000 people died from cancer in 2008,
representing about 8% of all estimated
global cancer deaths and about 6% of all
deaths in India.

Total Cancer Patients

1400000

International Agency for Research on

1200000
1000000
800000

Male
Female
Total

600000
400000
200000

Cancer prevalence in India is estimated to

2005 2006 2007 2008 2009 2010 2015 2020

be around 2.5 million, with over 800,000

new cases occurring each year. The absolute number of cancer deaths in India is projected to increase
because of population growth, urbanization, industrialization, lifestyle changes and increasing life
expectancy. World Health Organization (WHO) has estimated that the cancer death s in India are
projected to increase to 700,000 by 2015.
India is a culturally diverse country, with huge regional and rural-to-urban variation in lifestyles and in
age-specific adult death rates. A recent study found large variations in the type of cancer in various
regions and subpopulations of India. It concluded that:

More than 70% of fatal cancers occur in productive ages of 3069 years.

Rates of cancer deaths were generally similar between rural and urban areas and about twice as
high in the least versus the most educated.

A large proportion of cancer deaths in middle age (3069 years) arise from tobacco-related
cancers, particularly in the northeastern states of India

Lip ,Oral cavity & Pharynx Cancer in Men & Cervical Cancer in woman is the most common cancer
responsible for the death in Indians, based on the study conducted & funded by Bill & Melinda Gates
foundation & US National Institute of Health

Graph 1:- Estimated rates of cancer mortality (1000s) for main cancer aged 3069
years (Men)

Graph 2:- Estimated rates of cancer mortality (1000s) for main cancer aged 3069 years (Women)

Oncology Trials in India

The oncology market in India is worth US$ 90 million and is expected to reach up to US$ 3,350 million by
2012, growing at a CAGR of nearly 30%.
According to a report global pharma majors would spend up to US$ 1.5 Billion in India for drug trials out
of which majority are expected to be in cancer.
Oncology is an area with significant unmet therapeutic needs. There is a dire need to promote and
support clinical trials of new cancer treatments, explore methods of cancer prevention and early
detection and also study quality-of-life issues and rehabilitation during and after the treatment of
cancer.
Advantages that India Offers:

Large population with increasing cancer incidence

The sheer number of diverse and advanced cancer cases offers a unique opportunity for carrying
out different trials in various parts of the country

Huge potential for clinical research material

Regional cancer centers in India

All conducting various levels of clinical research

Trained researchers with quality data

MNI Experience in Oncology Studies

Majority of the total studies done by MNI are oncology studies
which includes large Phase I to phase III trials in India. Currently
MNI is conducting oncology trials with many key opinion
leaders for wide range of cancer indications covering different
regions in India.
Max Neeman has dedicated teams working on these highly
challenging studies. All the Project Manager associated with
Max Neeman has an average experience of more than 5
years.The teams are trained periodically on various aspects of
oncology trials and ICH-GCP standards to ensure the highest
quality standards to achieve the study objectives.

Percentage of Oncology trials among other therapeutic

areas

Max Neeman boasts of long term association with some of Indias most reputed
cancer institutions and oncologists. Combined with MNIs years of experience in oncology-specific
clinical trials, this has lead to high patient recruitment and retention rates, and lower overall costs for its
clients.
MNI unparalleled oncology expertise includes network of:

8+ Oncology Project Managers

More than 20 CRA with experience in monitoring oncology clinical trials

250+ Sites in 43 cities.

Sample List of Studies Conducted by MNI in Oncology (Indication-Wise)

S. No

Indication

Total Studies done by MNI

Breast Carcinoma

13

NSCLC

11

SCLC

Ovarian Carcinoma

16

Pancreatic Carcinoma

13

Advance Carcinoma

12

Bowel Dysfunction Ca Patients

Chronic Lymphocytic Leukemia

Non Hodgkins Lymphoma

10

Prostate Cancer

11

Gastro oesophageal Junction Adenocarcinoma

12

Colorectal Adenocarcinoma

13

CINV

14

Chemotherapy induced Anemia

15

Renal Cell Carcinoma

16

Chronic Myeloid Leukemia

17

Lymphoma

18

Tumour Tissue Collection

19

Ca Cervix

11

20

Metastatic Pancreatic Cancer